Sherbrooke, Qu\u00e9bec – January 15th, 2026 Diex Research announces the official opening of its new Phase 1 clinical research facilities located in the eastern part of Sherbrooke. This expansion marks a strategic milestone for early-stage clinical research in Qu\u00e9bec and reinforces the province\u2019s capacity to actively contribute to the global development of innovative therapies.<\/p>\r\n
\r\nThis expansion represents a strategic investment in a critical segment of the clinical research continuum. Phase 1 trials, including first-in-human studies, are essential to translating scientific discovery into real-world therapies. y strengthening this capability in Sherbrooke, Diex contributes to positioning Qu\u00e9bec as a competitive and attractive hub within the international clinical research landscape, while fostering collaboration between researchers, clinicians, and industry partners.<\/p>\r\n
\r\n\u201cPhase 1 research is where innovation truly begins. By expanding our Phase 1 capacity in Sherbrooke, we are helping Qu\u00e9bec retain its talent, attract global research partnerships, and bring promising therapies to patients faster,\u201d says Suzie Talbot, President and co-founder of Diex Research.<\/p>\r\n
\r\nA STRATEGIC ASSET FOR QU\u00c9BEC\u2019S LIFE SCIENCES ECOSYSTEM<\/p>\r\n
Phase 1 infrastructure is a key driver of innovation, economic growth, and scientific leadership. With this new unit, Diex Research contributes to several advancements:
\r\n– Enhanced early-stage clinical trial capacity in Qu\u00e9bec
\r\n– Faster study start-up and execution
\r\n– Improved patient access to innovative therapies
\r\n– Strengthened local expertise in clinical research operations
\r\n– This project represents a $1.5 million investment, underscoring Diex\u2019s commitment to building advanced clinical research infrastructure and supporting the sustainable growth of Qu\u00e9bec\u2019s life sciences sector.<\/p>\r\n
OFFICIAL INAUGURATION WITH HEALTH LEADERS AND INNOVATION STAKEHOLDERS\u00a0<\/p>\r\n
The inauguration will take place during a 4-7 PM reception, bringing together elected officials, physicians, healthcare partners, and representatives from the pharmaceutical industry. Attendees will have the opportunity to tour the new facility and engage in discussions about the strategic importance of Phase 1 clinical research in advancing innovative therapies. At a time when access to early-stage clinical research infrastructure is a key driver of competitiveness and investment attraction, this expansion positions Sherbrooke as a growing center for advanced clinical research.<\/p>\r\n